Status:

TERMINATED

A Study of the Efficacy of Preventive Dosing of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism (VTE) in Patients Undergoing Coronary Bypass Surgery Receiving Routine Mechanical Prophylaxis

Lead Sponsor:

Prairie Education and Research Cooperative

Collaborating Sponsors:

American College of Phlebology

Conditions:

Deep Vein Thrombosis

Coronary Artery Bypass Surgery

Eligibility:

All Genders

18-90 years

Phase:

NA

Brief Summary

This trial is a prospective, single-center Phase II randomized study to demonstrate the superior efficacy of Fondaparinux Sodium subcutaneous injections in patients undergoing CABG surgery (isolated a...

Detailed Description

Background Information Venous thromboembolism (VTE) following coronary artery bypass graft (CABG) surgery is a formidable risk in view of various predisposing factors including restriction of activit...

Eligibility Criteria

Inclusion

  • Subject Inclusion Criteria In order to be enrolled in the study, subjects must meet all of the inclusion criteria as listed below.
  • Consecutive patients undergoing isolated or redo isolated CABG
  • Patients must provide written informed consent
  • Patients must agree to comply with study procedures for the entire length of the study.
  • Must be 18 years old or greater.
  • Subject Exclusion Criteria Any subject that meets any of the exclusion criteria listed below at baseline will be excluded from study participation.
  • Patients with medical history that requires chronic anticoagulation with unfractionated heparin or coumadin or LMWH or heparinoids (i.e. previous DVT, pulmonary embolism, atrial fibrillation, heart valve replacement)
  • Patients with contraindications to anticoagulation (coagulopathy e.g, INR\>/=1.5, generalized bleeding disorders, peptic ulcer disease, hemorrhagic or ischemic stroke, etc within last 3 months)
  • Patients who are unable to undergo a doppler ultrasound of the lower extremities
  • Renal insufficiency (creatinine clearance \< 30 mL/min)
  • Patients who have a body weight \< 50 kg
  • Patients receiving continuous (indwelling) epidural
  • Physician diagnosed acute or chronic hepatic failure
  • Pregnancy
  • Patients with life expectancy \< 6 months
  • Platelet count below 100,000/ mm-3
  • History of documented VTE within last 3 months.
  • Acute bacterial endocarditis
  • Cerebral metastasis or abscess
  • Inability to consent
  • Refusal by treating physician

Exclusion

    Key Trial Info

    Start Date :

    November 19 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 21 2013

    Estimated Enrollment :

    78 Patients enrolled

    Trial Details

    Trial ID

    NCT00789399

    Start Date

    November 19 2009

    End Date

    September 21 2013

    Last Update

    September 8 2022

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.